Pharmaceuticals News and Research

RSS

New treatment slows the growth of colon and liver cancers

Leire Garcia Navarro, a researcher at the School of Pharmacy of the University of Navarra, has developed a new treatment which slows the growth of colon and liver cancers.

23 Jun 2007

Ranbaxy receives tentative FDA approval for Tamsulosin capsules

Ranbaxy Pharmaceuticals has announced that RLL has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Tamsulosin Hydrochloride Capsules, 0.4 mg.

23 Jun 2007

PhytoLabs granted U.S. patent for immuno-stimulatory dietary supplement

The PhytoLabs group of companies, holder of the world wide rights to the newly released University of Mississippi's immuno-stimulatory dietary supplement, is very pleased to announce that Patent #7,205,284 for Potent Immunostimulants from Microalgae has been issued by the U.S. Patent and Trademark Office (USPTO).

23 Jun 2007

Vaccine for human cytomegalovirus

Researchers at the University of California, San Diego (UCSD) Skaggs School of Pharmacy and Pharmaceutical Sciences have patented a strategy for developing a human vaccine to prevent against Human Cytomegalovirus (hCMV) infection and disease.

23 Jun 2007

New compound kills fungal pathogens

A new mechanism to attack hard-to-treat fungal infections has been revealed by scientists from the biotech company Anacor Pharmaceuticals Inc., California, and the European Molecular Biology Laboratory (EMBL) outstation in Grenoble, France.

23 Jun 2007

Experimental Alzheimer's drug begins clinical trials

A drug based on the design of a Purdue University researcher to treat Alzheimer's disease began the first phase of human clinical trials this week.

23 Jun 2007

New cancer drug target

Research led by scientists at Weill Cornell Medical College has uncovered two new potential points of vulnerability on a key cancer-promoting protein, called XIAP.

23 Jun 2007

New drug target for the treatment of Parkinson's disease

Researchers at the MassGeneral Institute for Neurodegenerative Disease (MGH-MIND) have identified a potential new drug target for the treatment of Parkinson's disease and possibly for other degenerative neurological disorders.

23 Jun 2007

New risk marker for overweight children

A study of 40 overweight children in Edmonton has revealed they all share something in common aside from being heavy: each one of them has high levels of apoB48, a structural protein found in intestinal cholesterol.

23 Jun 2007

New hope for Alzheimer's disease

Scientists have provided new details about how proteins used to destroy bacteria and viruses may help treat Alzheimer?s disease.

23 Jun 2007

Inherited genes linked to toxicity of leukemia therapy

St. Jude investigators have discovered inherited variations in certain genes that make children with acute lymphoblastic leukemia (ALL) susceptible to the toxic side effects caused by chemotherapy medications.

23 Jun 2007

Arpida receives FDA approval to initiate Phase II trial with intravenous iclaprim

Arpida Ltd. has announced that it has received approval from the US Food and Drug Administration for a Phase II trial with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare-associated pneumonia (HCAP) suspected or confirmed to be due to Gram-positive pathogens.

23 Jun 2007

Anacor finds novel mechanism for lead anti-fungal drug, AN2690

Anacor Pharmaceuticals, a privately held pharmaceutical company, has announced that the journal Science will publish results of research that details how AN2690, the company's lead clinical candidate, kills fungal cells by interfering with synthesis of a specific protein required for fungal growth.

23 Jun 2007

New treatment slows the growth of colon and liver cancers

A. Navarro, a researcher at the School of Pharmacy of the University of Navarra, has developed a new treatment which slows the growth of colon and liver cancers.

23 Jun 2007

Ranbaxy receives tentative approval to manufacture Amlodipine Besylate tablets

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced that RLL has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Amlodipine Besylate Tablets, 2.5 mg (base), 5 mg (base) and 10 mg (base).

23 Jun 2007

Key mechanism identified by which the body regulates iron metabolism

Scientists at the University of California, San Diego (UCSD) have determined a key mechanism by which the body regulates iron metabolism, a discovery that may provide new approaches for the treatment of anemia.

23 Jun 2007

New trade agreement language to allow developing countries more flexibility in circumventing drug patents, other restrictions

Democratic lawmakers and U.S. trade officials are in the final stages of negotiation over language to be added to international free trade agreements that would allow developing countries more flexibility in circumventing drug patents and other restrictions on pharmaceuticals, sources said recently, CongressDaily reports.

22 Jun 2007

Report examines programs that would give HIV-positive people access to new drugs before final federal approval

"Rethinking the Approach to Expanded Access Programs," Forum for Collaborative HIV Research: The report says that reform of expanded access programs that allow HIV-positive people to take new drugs before final federal approval is needed.

22 Jun 2007

Texas sues three drug makers alleging Medicaid fraud

Texas on Wednesday filed lawsuits against Mylan Laboratories, Sandoz, Teva Pharmaceuticals and subsidiaries of those companies alleging that the state Medicaid program overpaid retailers by at least tens of millions of dollars for medications because the companies did not disclose discounts they were providing to retailers, the Houston Chronicle reports.

22 Jun 2007

Stem cells to repair damaged heart muscle

In the first trial of its kind in the world, 60 patients who have recently suffered a major heart attack will be injected with selected stem cells from their own bone marrow during routine coronary bypass surgery.

22 Jun 2007